The Effect of Selenium Supplementation on Levels of Gene Expression Associated with Insulin and Lipid Metabolism and Inflammatory Markers in Diabetic Hemodialysis Patients

Abstract

Aim: The aim of this trial was to determine the effects of selenium supplementation on the levels of genes expression associated with insulin, lipid and inflammatory markers in diabetic hemodialysis patients. Methods: This randomized, double-blind, placebo-controlled clinical trial was done on forty diabetic hemodialysis patients. The study subjects were divided into two groups by random to take either 200 µg/day selenium (n=20) or placebo (n=20) during 24 weeks. Results: Selenium intake led to upregulation of peroxisome proliferator-activated receptor gamma (PPAR-γ) (1.08+0.22 vs. 0.93+0.18 fold change, P=0.049), LDL-receptor (1.06+0.14 vs. 0.90+0.16 fold change, P=0.008) and transforming the growth of factor beta (TGF-β) (1.15+0.18 vs. 0.91+0.20 fold change, P=0.002) in the levels of gene expression. In comparison with placebo, in this intervention also reduction of gene expression of tumor necrosis factor alpha (TNF-α) (0.90+0.19 vs. 1.08+0.19 fold change, P=0.014) and interleukin-1 (IL-1) (1.00+0.11 vs. 1.12+0.15 fold change, P=0.020) were detected. In this study, gene expression of vascular endothelial growth factor (VEGF) (1.02+0.13 vs. 0.96+0.18 fold change, P=0.333) and (IL-8) (0.98+0.20 vs. 1.03+0.17 fold change, P=0.458) were not affected by selenium supplementation. Conclusion: Selenium supplementation during 24 weeks had positive effects on gene expression associated with metabolic status inflammatory markers in diabetic hemodialysis patients.